{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [["challenge models", "chronic obstructive pulmonary disease", "therapy assessment"]], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "23055710", "DateCompleted": {"Year": "2013", "Month": "01", "Day": "16"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": ["10.2147/COPD.S30664"], "ArticleDate": [{"Year": "2012", "Month": "09", "Day": "13"}], "Journal": {"ISSN": "1178-2005", "JournalIssue": {"Volume": "7", "PubDate": {"Year": "2012"}}, "Title": "International journal of chronic obstructive pulmonary disease", "ISOAbbreviation": "Int J Chron Obstruct Pulmon Dis"}, "ArticleTitle": "Challenge models to assess new therapies in chronic obstructive pulmonary disease.", "Pagination": {"StartPage": "597", "EndPage": "605", "MedlinePgn": "597-605"}, "Abstract": {"AbstractText": ["Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. Current therapies confer partial benefits either by incompletely improving airflow limitation or by reducing acute exacerbations, hence new therapies are desirable. In the absence of robust early predictors of clinical efficacy, the potential success of novel therapeutic agents in COPD will not entirely be known until the drugs enter relatively large and costly clinical trials. New predictive models in humans, and new study designs are being sought to allow for confirmation of pharmacodynamic and potentially clinically meaningful effects in early development. This review focuses on human challenge models with lipopolysaccharide endotoxin, ozone, and rhinovirus, in the early clinical development phases of novel therapeutic agents for the treatment and reduction of exacerbations in COPD."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Respiratory Clinical Development, MedImmune Ltd, Cambridge, UK. vandermerwer@medimmune.com"}], "Identifier": [], "LastName": "van der Merwe", "ForeName": "Ren\u00e9", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Molfino", "ForeName": "Nestor A", "Initials": "NA"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Int J Chron Obstruct Pulmon Dis", "NlmUniqueID": "101273481", "ISSNLinking": "1176-9106"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adrenal Cortex Hormones"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Bronchodilator Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Lipopolysaccharides"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Adrenal Cortex Hormones"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Bronchodilator Agents"}, {"QualifierName": [], "DescriptorName": "Cells, Cultured"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Evaluation, Preclinical"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Lipopolysaccharides"}, {"QualifierName": ["drug effects", "immunology", "physiopathology", "virology"], "DescriptorName": "Lung"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Ozone"}, {"QualifierName": ["drug therapy", "immunology", "physiopathology", "virology"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}, {"QualifierName": ["pathogenicity"], "DescriptorName": "Rhinovirus"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD.  [Accessed August 2, 2012].  [updated 2011]. Available at:  http://www.goldcopd.org."}, {"Citation": "American Lung Association. Chronic obstructive pulmonary disease (COPD) fact sheet.  [Accessed August 2, 2012].  [updated Feb 2011]. Available at:  http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html#note_12."}, {"Citation": "European COPD Coalition. Key facts.  [Accessed August 2, 2012].  [updated 2011]. Available at:  http://www.copdcoalition.eu/about-copd/key-facts."}, {"Citation": "Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332\u2013338.", "ArticleIdList": ["18511702"]}, {"Citation": "Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest. 2007;131(3):682\u2013689.", "ArticleIdList": ["17356080"]}, {"Citation": "Calverley PM, Anderson JA, Celli B, et al. for Torch investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775\u2013789.", "ArticleIdList": ["17314337"]}, {"Citation": "Celli B, Decramer M, Kesten S, et al. for UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948\u2013955.", "ArticleIdList": ["19729663"]}, {"Citation": "Rietschel ET, Schade U, Jensen M, Wollenweber HW, L\u00fcderitz O, Greisman SG. Bacterial endotoxins: chemical structure, biological activity and role in septicaemia. Scand J Infect Dis Suppl. 1982;31:8\u201321.", "ArticleIdList": ["7048515"]}, {"Citation": "Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42(4):145\u2013151.", "ArticleIdList": ["18304834"]}, {"Citation": "Michel O, Nagy AM, Schroeven M, et al. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med. 1997;156(4 Pt 1):1157\u20131164.", "ArticleIdList": ["9351616"]}, {"Citation": "Loh LC, Vyas B, Kanabar V, Kemeny DM, O\u2019Connor BJ. Inhaled endotoxin in healthy human subjects: a dose-related study on systemic effects and peripheral CD4+ and CD8+ T cells. Respir Med. 2006;100(3):519\u2013528.", "ArticleIdList": ["16039108"]}, {"Citation": "O\u2019Grady NP, Preas HL, Pugin J, et al. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med. 2001;163(7):1591\u20131598.", "ArticleIdList": ["11401879"]}, {"Citation": "Michel O, Dentener M, Cataldo D, et al. Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. Pulm Pharmacol Ther. 2007;20(6):676\u2013683.", "ArticleIdList": ["17045826"]}, {"Citation": "ClinicalTrials.gov. Simvastatin therapy for moderate and severe COPD (STATCOPE)  [Accessed August 2, 2012].  [updated April 23, 2012]. Available at:  http://clinicaltrials.gov/ct2/show/NCT01061671?term=NCT01061671&rank=1."}, {"Citation": "Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21(4):616\u2013623.", "ArticleIdList": ["18374614"]}, {"Citation": "Alexis NE, Peden DB. Blunting airway eosinophilic inflammation results in a decreased airway neutrophil response to inhaled LPS in patients with atopic asthma: a role for CD14. J Allergy Clin Immunol. 2001;108(4):577\u2013580.", "ArticleIdList": ["11590384"]}, {"Citation": "Bernstein JA, Alexis N, Barnes C, et al. Health effects of air pollution. J Allergy Clin Immunol. 2004;114(5):1116\u20131123.", "ArticleIdList": ["15536419"]}, {"Citation": "Peden DB. Air pollution in asthma: effect of pollutants on airway inflammation. Ann Allergy Asthma Immunol. 2001;87(6 Suppl 3):S12\u2013S17.", "ArticleIdList": ["11770676"]}, {"Citation": "Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. Health effects of outdoor air pollution. Am J Respir Crit Care Med. 1996;153(1):3\u201350.", "ArticleIdList": ["8542133"]}, {"Citation": "Aris RM, Christian D, Hearne PQ, Kerr K, Finkbeiner WE, Balmes JR. Ozone-induced airway inflammation in human subjects as determined by airway lavage and biopsy. Am Rev Respir Dis. 1993;148(5):1363\u20131372.", "ArticleIdList": ["8239177"]}, {"Citation": "Devlin RB, McDonnell WF, Mann R, et al. Exposure of humans to ambient levels of ozone for 6.6 hours causes cellular and biochemical changes in the lung. Am J Respir Cell Mol Biol. 1991;4(1):72\u201381.", "ArticleIdList": ["1846079"]}, {"Citation": "Alexis NE, Lay JC, Hazucha M, et al. Low-level ozone exposure induces airways inflammation and modifies cell surface phenotypes in healthy humans. Inhal Toxicol. 2010;22(7):593\u2013600.", "ArticleIdList": ["PMC3162473", "20384440"]}, {"Citation": "Kehrl HR, Hazucha MJ, Solic JJ, Bromberg PA. Responses of subjects with chronic obstructive pulmonary disease after exposures to 0.3 ppm ozone. Am Rev Respir Dis. 1985;131(5):719\u2013724.", "ArticleIdList": ["4003916"]}, {"Citation": "Holz O, Tal-Singer R, Kanniess F, et al. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol. 2005;45(5):498\u2013503.", "ArticleIdList": ["15831772"]}, {"Citation": "Alexis NE, Lay JC, Haczku A, et al. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect. 2008;116(6):799\u2013805.", "ArticleIdList": ["PMC2430237", "18560537"]}, {"Citation": "Schelegle ES, Adams WC, Siefkin AD. Indomethacin pretreatment reduces ozone-induced pulmonary function decrements in human subjects. Am Rev Respir Dis. 1987;136(6):1350\u20131354.", "ArticleIdList": ["3688637"]}, {"Citation": "Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J. 2010;35(3):564\u2013570.", "ArticleIdList": ["19643947"]}, {"Citation": "Nightingale JA, Rogers DF, Chung KF, Barnes PJ. No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med. 2000;161(2 Pt 1):479\u2013486.", "ArticleIdList": ["10673189"]}, {"Citation": "Hazucha MJ, Madden M, Pape G, et al. Effects of cyclo-oxygenase inhibition on ozone-induced respiratory inflammation and lung function changes. Eur J Appl Physiol Occup Physiol. 1996;73(1\u20132):17\u201327.", "ArticleIdList": ["8861665"]}, {"Citation": "Gaga M, Nair PK, Hargreave F, Sadeh J, Chanez P. SCH527123, a novel treatment option for severe neutrophilic asthma. Am J Respir Crit Care Med. 2010;181:A6763."}, {"Citation": "Lazaar AL, Sweeney LE, Macdonald AJ, Alexis NE, Chen C, Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex-vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011;72(2):282\u2013293.", "ArticleIdList": ["PMC3162658", "21426372"]}, {"Citation": "Linn WS, Fischer DA, Medway DA, et al. Short-term respiratory effects of 0.12 ppm ozone exposure in volunteers with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1982;125(6):658\u2013663.", "ArticleIdList": ["7091871"]}, {"Citation": "Solic JJ, Hazucha MJ, Bromberg PA. The acute effects of 0.2 ppm ozone in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1982;125(6):664\u2013669.", "ArticleIdList": ["6807152"]}, {"Citation": "Linn WS, Shamoo DA, Venet TG, et al. Response to ozone in volunteers with chronic obstructive pulmonary disease. Arch Environ Health. 1983;38(5):278\u2013283.", "ArticleIdList": ["6651352"]}, {"Citation": "Gong H, Jr, Shamoo DA, Anderson KR, Linn WS. Responses of older men with and without chronic obstructive pulmonary disease to prolonged ozone exposure. Arch Environ Health. 1997;52(1):18\u201325.", "ArticleIdList": ["9039853"]}, {"Citation": "Gern JE, Galagan DM, Jarjour NN, Dick EC, Busse WW. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med. 1997;155(3):1159\u20131161.", "ArticleIdList": ["9117003"]}, {"Citation": "Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell. 1989;56(5):839\u2013847.", "ArticleIdList": ["2538243"]}, {"Citation": "Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci U S A. 1994;91(5):1839\u20131842.", "ArticleIdList": ["PMC43259", "8127891"]}, {"Citation": "Griego SD, Weston CB, Adams JL, Tal-Singer R, Dillon SB. Role of p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells. J Immunol. 2000;165(9):5211\u20135220.", "ArticleIdList": ["11046054"]}, {"Citation": "Donninger H, Glashoff R, Haitchi HM, et al. Rhinovirus induction of the CXC chemokine epithelial-neutrophil activating peptide-78 in bronchial epithelium. J Infect Dis. 2003;187(11):1809\u20131817.", "ArticleIdList": ["12751040"]}, {"Citation": "Johnston SL, Papi A, Bates PJ, Mastronarde JG, Monick MM, Hunninghake GW. Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. J Immunol. 1998;160(12):6172\u20136181.", "ArticleIdList": ["9637536"]}, {"Citation": "Mosser AG, Vrtis R, Burchell L, et al. Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues. Am J Respir Crit Care Med. 2005;171(6):645\u2013651.", "ArticleIdList": ["15591468"]}, {"Citation": "Papadopoulos NG, Bates PJ, Bardin PG, et al. Rhinoviruses infect the lower airways. J Infect Dis. 2000;181(6):1875\u20131884.", "ArticleIdList": ["10837165"]}, {"Citation": "Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med. 1995;151(3 Pt 1):879\u2013886.", "ArticleIdList": ["7881686"]}, {"Citation": "Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58(1):37\u201342.", "ArticleIdList": ["PMC1746460", "12511718"]}, {"Citation": "Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114\u20131121.", "ArticleIdList": ["16484677"]}, {"Citation": "Ko FW, Ip M, Chan PK, et al. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest. 2007;131(1):44\u201352.", "ArticleIdList": ["17218555"]}, {"Citation": "Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006;129(2):317\u2013324.", "ArticleIdList": ["PMC7094441", "16478847"]}, {"Citation": "Camargo CA, Jr, Ginde AA, Clark S, Cartwright CP, Falsey AR, Niewoehner DE. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med. 2008;3(4):355\u2013359.", "ArticleIdList": ["18825480"]}, {"Citation": "Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Repir Med. 2008;102(8):1109\u20131116.", "ArticleIdList": ["PMC7127638", "18573648"]}, {"Citation": "Scott EJ, Grist NR, Eadie MB. Rhinovirus infections in chronic bronchitis: isolation of eight possibly new rhinovirus serotypes. J Med Microbiol. 1968;1(1):109\u2013117.", "ArticleIdList": ["4318937"]}, {"Citation": "Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. Am Rev Respir Dis. 1976;113(4):465\u2013474.", "ArticleIdList": ["1267252"]}, {"Citation": "Philit F, Etienne J, Calvet A, et al. Infectious agents associated with exacerbations of chronic obstructive bronchopneumopathies and asthma attacks. Rev Mal Respir. 1992;9(2):191\u2013196. French.", "ArticleIdList": ["1565831"]}, {"Citation": "Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618\u20131623.", "ArticleIdList": ["11719299"]}, {"Citation": "Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(1):167\u2013173.", "ArticleIdList": ["10903237"]}, {"Citation": "Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res. 2006;7:116.", "ArticleIdList": ["PMC1578567", "16956406"]}, {"Citation": "Mallia P, Message S, Contoli M, et al.   [Accessed August 2, 2012];2006 61(Suppl 2):Sii3\u2013Sii56. Available from:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104786/"}, {"Citation": "Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183(6):734\u2013742.", "ArticleIdList": ["PMC3081284", "20889904"]}, {"Citation": "Crump CE, Arruda E, Hayden FG. Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule. Antimicrob Agents Chemother. 1994;38(6):1425\u20131427.", "ArticleIdList": ["PMC188225", "7916558"]}, {"Citation": "Turner RB, Wecker MT, Pohl G, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA. 1999;281(19):1797\u20131804.", "ArticleIdList": ["10340366"]}, {"Citation": "Savolainen C, Blomqvist S, Mulders MN, Hovi T. Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. J Gen Virol. 2002;83(Pt 2):333\u2013340.", "ArticleIdList": ["11807226"]}, {"Citation": "Saito T, Hirai R, Loo YM, et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A. 2007;104(2):582\u2013587.", "ArticleIdList": ["PMC1766428", "17190814"]}, {"Citation": "Hayden FG, Herrington DT, Coats TL, et al. for Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36(12):1523\u20131532.", "ArticleIdList": ["PMC7199898", "12802751"]}, {"Citation": "Arnold E, Luo M, Vriend G, et al. Implications of the picornavirus capsid structure for polyprotein processing. Proc Natl Acad Sci U S A. 1987;84(1):21\u201325.", "ArticleIdList": ["PMC304133", "3467351"]}, {"Citation": "K\u00f6nig H, Rosenwirth B. Purification and partial characterization of poliovirus protease 2A by means of a functional assay. J Virol. 1988;62(4):1243\u20131250.", "ArticleIdList": ["PMC253133", "2831385"]}, {"Citation": "Alexis NE, Lay JC, Almond M, Bromberg PA, Patel DD, Peden DB. Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo. J Allergy Clin Immunol. 2005;115(2):345\u2013350.", "ArticleIdList": ["15696093"]}]}], "History": [{"Year": "2012", "Month": "10", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2012", "Month": "10", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "1", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2012", "Month": "9", "Day": "13"}], "PublicationStatus": "ppublish", "ArticleIdList": ["23055710", "PMC3459659", "10.2147/COPD.S30664", "copd-7-597"]}}], "PubmedBookArticle": []}